Jane Street Group LLC Has $74,000 Stock Holdings in Veru Inc. (NASDAQ:VERU)

Jane Street Group LLC lifted its holdings in shares of Veru Inc. (NASDAQ:VERU) by 142.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 96,454 shares of the company’s stock after acquiring an additional 56,736 shares during the quarter. Jane Street Group LLC owned approximately 0.07% of Veru worth $74,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Perceptive Advisors LLC raised its holdings in Veru by 26.5% in the 2nd quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock valued at $5,942,000 after acquiring an additional 1,478,578 shares in the last quarter. State Street Corp boosted its position in shares of Veru by 4.3% during the 3rd quarter. State Street Corp now owns 2,072,065 shares of the company’s stock valued at $1,593,000 after purchasing an additional 84,483 shares in the last quarter. PVG Asset Management Corp acquired a new position in Veru during the 2nd quarter worth approximately $474,000. Bank of New York Mellon Corp raised its stake in shares of Veru by 1,718.2% in the second quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock worth $373,000 after purchasing an additional 419,374 shares during the last quarter. Finally, Blair William & Co. IL increased its position in shares of Veru by 6.1% during the second quarter. Blair William & Co. IL now owns 350,000 shares of the company’s stock valued at $294,000 after acquiring an additional 20,000 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors.

Veru Stock Down 0.4 %

Shares of Veru stock opened at $0.74 on Thursday. The firm has a market cap of $108.40 million, a price-to-earnings ratio of -1.54 and a beta of -0.53. The business has a 50-day moving average price of $0.69 and a 200-day moving average price of $0.80. Veru Inc. has a twelve month low of $0.36 and a twelve month high of $1.92.

Veru (NASDAQ:VERU) last announced its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. On average, equities analysts expect that Veru Inc. will post -0.3 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on VERU shares. Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Veru in a report on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Veru in a report on Thursday, January 2nd.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.